Educational Panel : The Art of the Exit: Planning for Your Company’s Acquisition

feb 12, 2018: middag - 12:55 p.m.
Salon 4

There are times when a company for reasons such as clinical trial expense, achieving scale in a global sales force, or needing manufacturing capacity, recognizes that shareholder returns are best served by being acquired by a strategic buyer.  Leadership teams that manage their process well can maximize the eventual benefits for their shareholders, employees, and patients of this transformation through careful partner identification, negotiations management, and integration planning.  This session will feature experienced perspectives on the do’s and don’ts for CEOs considering options for proactive selling of their companies, rather than just reacting to external purchase offers.


Moderator: Kimberly C. Petillo-Décossard, Partner, Cahill Gordon & Reindel LLP


Janelle Anderson, PhD, Entrepreneur-in-Residence, Versant Ventures

Peter J. Collum, Partner, MTS Health Partners

Derek Hicks, Senior Director, Worldwide Business Development, Pfizer Inc.

Neil Warma, Director, Orpheris; former President & Chief Executive Officer, Opexa Therapeutics, Inc. 


Peter J. Collum

Janelle Anderson, PhD

Derek Hicks
Senior Director, World...

Neil Warma
Director, Orpheris; Pr...